Recent data from the Food and Drug Administration’s Adverse Event Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of Reglan (or its generic version, metoclopramide) more than doubled between 2006 and 2008. In February 2009, the FDA forced the manufacturers of Reglan and metoclopramide to add a black-box warning to their labels about the strong connection between tardive dyskinesia and the long-term use of Reglan.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.